Clinical outcomes of volume of disease on patients receiving enzalutamide
abiraterone acetate
enzalutamide
metastatic castration-resistant prostate cancer
overall survival
volume of disease
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
10
2022
accepted:
21
01
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) benefits and there is no consensus upon the best option for mCRPC first-line treatment. Volume of disease may represent a useful biomarker to predict response to therapy in such patients. In this study, we seek to evaluate the impact of volume of disease on patients treated with first-line AA We retrospectively evaluated a cohort of consecutive patients with mCRPC categorized by volume of disease [high volume (HV) or low volume (LV) per E3805 criteria] at ARSi onset and treatment type (AA or Enza), assessing OS and radiographic progression-free survival (rPFS), from therapy start, as co-primary endpoints. Of the 420 patients selected, 170 (40.5%) had LV and received AA (LV/AA), 76 (18.1%) LV and had Enza (LV/Enza), 124 (29.5%) HV and were given AA (HV/AA), and 50 (11.9%) HV and received Enza (HV/Enza). Among patients with LV, OS was significantly longer when treated with Enza [57.2 months; 95% confidence interval (CI): 52.1-62.2 months] Within the intrinsic limitations of a retrospective design and small population, our report suggests that volume of disease could be a useful predictive biomarker for patients starting first-line ARSi for mCRPC.
Sections du résumé
Background
UNASSIGNED
Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) benefits and there is no consensus upon the best option for mCRPC first-line treatment. Volume of disease may represent a useful biomarker to predict response to therapy in such patients.
Objectives
UNASSIGNED
In this study, we seek to evaluate the impact of volume of disease on patients treated with first-line AA
Design and methods
UNASSIGNED
We retrospectively evaluated a cohort of consecutive patients with mCRPC categorized by volume of disease [high volume (HV) or low volume (LV) per E3805 criteria] at ARSi onset and treatment type (AA or Enza), assessing OS and radiographic progression-free survival (rPFS), from therapy start, as co-primary endpoints.
Results
UNASSIGNED
Of the 420 patients selected, 170 (40.5%) had LV and received AA (LV/AA), 76 (18.1%) LV and had Enza (LV/Enza), 124 (29.5%) HV and were given AA (HV/AA), and 50 (11.9%) HV and received Enza (HV/Enza). Among patients with LV, OS was significantly longer when treated with Enza [57.2 months; 95% confidence interval (CI): 52.1-62.2 months]
Conclusion
UNASSIGNED
Within the intrinsic limitations of a retrospective design and small population, our report suggests that volume of disease could be a useful predictive biomarker for patients starting first-line ARSi for mCRPC.
Identifiants
pubmed: 36895852
doi: 10.1177/17588359231156147
pii: 10.1177_17588359231156147
pmc: PMC9989439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231156147Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
Loana Bueno Valenca received consulting fees from Janssen and travel grants from Janssen, Astellas, Bayer. The other authors report no conflict of interest.
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Genitourin Cancer. 2020 Aug;18(4):284-294
pubmed: 32057714
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Curr Opin Urol. 2017 Nov;27(6):596-603
pubmed: 28786849
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951